Merck May Face $2 Bil. Tax Bill; Medco Transactions Subject Of IRS Notice
Merck is facing a potential $2 bil. back tax liability arising out of a "partnership transaction" tied to the 1993 Medco acquisition
You may also be interested in...
GlaxoSmithKline and the Internal Revenue Service are headed to court over the IRS' conclusion that the company owes $5.2 bil. for unpaid taxes, penalty charges and interest
MERCK MARKET SHARE ON MEDCO FORMULARIES REACHES 12%, UP FROM 10%; MERCK WILL NOT BROADEN PRODUCT LINE TO MAINTAIN MARKET SHARE, CEO GILMARTIN TELLS NYSSA
Merck products have climbed to a 12% share of Medco formulary product sales, Merck Chairman and CEO Ray Gilmartin told a meeting of the New York Society of Security Analysts Nov. 29.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011